News
One VA Cancer Pathway to Rule Them All?
- Author:
- Randy Dotinga
The US Department of Veterans Affairs (VA) has developed clinical pathways to guide its clinicians through cancer...
News
Telitacicept shows efficacy, safety in methotrexate-resistant RA
- Author:
- Randy Dotinga
The investigational drug’s ACR 20 response rate was typical for RA biologic treatments, and the trial’s Chinese patient population didn’t include...
News
Novel blood test can detect RA
- Author:
- Randy Dotinga
An experimental assay detects epigenetic features within the unique patterns and sizes of cell-free DNA found in blood, but is it better than...
News
IV secukinumab, alternative to self-injections, reaches primary endpoints in PsA, axSpA
- Author:
- Randy Dotinga
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and...
News
Physician’s dispute with Mayo Clinic raises free speech, academic freedom concerns
- Author:
- Randy Dotinga
“Joyner said he’s ‘frustrated’ with the NIH’s ‘bureaucratic rope-a-dope,’ calling the agency’s guidelines ‘a wet blanket.’ ”
News
Study takes fine-grained look at MACE risk with glucocorticoids in RA
- Author:
- Randy Dotinga
The level of risk for MACE rose with the dose, duration, and recency of GC use, and risk increased significantly at prednisone-equivalent doses as...
News
Apremilast beats placebo in early PsA affecting few joints
- Author:
- Randy Dotinga
Phase 4 trial offers insight into efficacy in patients whose mild cases have gotten less research attention.
News
FDA’s Project Optimus aims to transform early cancer research
- Author:
- Randy Dotinga
Q & A with an expert on how the FDA’s Project Optimus targets toxicity and how it could spell the end of traditional dose-escalation trials....
News
Caution raised on reduced-dose steroids in rare vasculitides GPA, MPA
- Author:
- Randy Dotinga
A real-world analysis finds that some patients who receive reduced-dose glucocorticoids may have a higher risk of poor outcomes.
News
CPPD nomenclature is sore subject for gout group
- Author:
- Randy Dotinga
G-CAN hopes to standardize terminology and finally oust ‘pseudo’ vernacular.
News
Gout: Studies support early use of urate-lowering therapy, warn of peripheral arterial disease
- Author:
- Randy Dotinga
Urate-lowering drugs might be OK early on; gout may boost peripheral arterial disease.
News
T-cell cancers: CAR T therapy to the rescue?
- Author:
- Randy Dotinga
Trials are small and incomplete, but CAR T-cell therapy has yielded promising early results in treating T-cell blood cancers.
News
84-year-old MD contests employer’s mandatory cognitive tests for older docs
- Author:
- Randy Dotinga
According to the lawsuit, the hospital illegally required neuropsychological and eye examinations of physicians aged 70 or older who sought to...
News
How Does Military Service Impact Cancer Risk? It’s Complicated
- Author:
- Randy Dotinga
While it’s extremely difficult to link cancer rates to military service, researchers are starting to get some initial...
News
MS, DMTs, and pregnancy: Beware of over-caution regarding treatment
- Author:
- Randy Dotinga
Don’t be too quick to stop therapy or too slow to restart it, researcher tells ECTRIMS audience.